Gainers
- Polyrizon (NASDAQ:PLRZ) stock rose 8.5% to $1.15 during Thursday's after-market session. The company's market cap stands at $6.1 million.
- Prenetics Global (NASDAQ:PRE) stock rose 7.1% to $8.59. The market value of their outstanding shares is at $104.9 million. As per the news, the Q1 earnings report came out today.
- Adaptimmune Therapeutics (NASDAQ:ADAP) stock moved upwards by 7.07% to $0.26. The company's market cap stands at $69.7 million.
- Scilex Holding (NASDAQ:SCLX) stock moved upwards by 6.58% to $5.5. The market value of their outstanding shares is at $30.2 million.
- Nuwellis (NASDAQ:NUWE) shares rose 5.91% to $0.33. The company's market cap stands at $1.4 million.
- Health Catalyst (NASDAQ:HCAT) stock increased by 5.52% to $4.2. The company's market cap stands at $292.3 million.
Losers
- Healthcare Triangle (NASDAQ:HCTI) stock fell 16.3% to $0.03 during Thursday's after-market session. The company's market cap stands at $10.2 million.
- Rein Therapeutics (NASDAQ:RNTX) shares declined by 12.7% to $1.72. The market value of their outstanding shares is at $38.1 million.
- Liminatus Pharma (NASDAQ:LIMN) shares decreased by 10.79% to $18.12. The company's market cap stands at $471.3 million.
- bioAffinity Technologies (NASDAQ:BIAF) shares declined by 8.63% to $0.28. The market value of their outstanding shares is at $7.5 million.
- Compass Pathways (NASDAQ:CMPS) stock decreased by 8.19% to $4.15. The market value of their outstanding shares is at $388.2 million.
- NuCana (NASDAQ:NCNA) shares decreased by 6.52% to $0.14. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
CMPSCompass Pathways PLC
$5.13-0.77%
HCATHealth Catalyst Inc
$2.36-%
HCTIHealthcare Triangle Inc
$1.85-3.14%
LIMNLiminatus Pharma Inc
$0.76336.19%
NCNANuCana PLC
$3.43-1.86%
NUWENuwellis Inc
$2.01-1.95%
PLRZPolyrizon Ltd
$0.6322-0.58%
PREPrenetics Global Ltd
$12.68-%
RNTXRein Therapeutics Inc
$1.32-10.8%
SCLXScilex Holding Co
$23.815.77%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
